Search Results

You are looking at 271 - 280 of 2,910 items for :

  • Refine by Access: All x
Clear All
Full access

HSR21-073: Febrile Neutropenia Outcomes Among Patients With Breast Cancer and Non-Hodgkin’s Lymphoma Receiving Pegfilgrastim Prophylaxis: A Real-World Analysis of Commercial and Medicare Claims From 2017-2018

Weijia Wang, Edward Li, Kim Campbell, and Ali McBride

Introduction: Febrile neutropenia (FN) is a major dose-limiting toxicity of myelosuppressive chemotherapy that can result in hospitalization, dose reductions or treatment delays and compromised clinical outcomes. National Comprehensive Cancer

Full access

HSR22-141: Treatment Patterns and Clinical Outcomes Among Metastatic Non-Small Cell Lung Cancer Patients Without Actionable Genomic Alterations (AGAs) Previously Treated With Platinum-Based Chemotherapy and Immunotherapy

Jerome H Goldschmidt, Anupama Vasudevan, Michelle Silver, Jackie Kwong, and Elizabeth Marrett

1. Clinical Outcomes by Subsequent Treatment *Other sTx group not shown due to small sample size

Full access

Delivering on the Promise of Patient-Centered Care

Patricia A. Ganz

Despite our success in improving survival outcomes in patients with cancer, the words “you have cancer” are still terrifying. These 3 words immediately conjure up the threat of death and the physical and emotional suffering associated with cancer

Full access

NCCN Framework for Resource Stratification: A Framework for Providing and Improving Global Quality Oncology Care

Robert W. Carlson, Jillian L. Scavone, Wui-Jin Koh, Joan S. McClure, Benjamin E. Greer, Rashmi Kumar, Nicole R. McMillian, and Benjamin O. Anderson

mature and organized health care infrastructure. They make no recommendations about how resource expenditures should be prioritized to achieve the greatest clinical benefit and outcome. Most of the currently available clinical practice guidelines, such as

Full access

HSR20-102: Quality Outcomes in Colon Cancer

Michelle Moskal and Neeharika S. Makani

Full access

A Systematic Review of Clinical Decision Support Systems for Clinical Oncology Practice

Pamala A. Pawloski, Gabriel A. Brooks, Matthew E. Nielsen, and Barbara A. Olson-Bullis

-based standardization of cancer care, improving care delivery and patient outcomes. CDS tools have been incorporated across the patient care spectrum, encompassing prevention, diagnosis, and clinical monitoring. Common roles for CDS include computerized physician order

Full access

Plenary Session—The Patient Journey: Cancer Survivor Care

Presented by: Shannon M. Ansbaugh, Gary Deng, Rev. George F. Handzo, and Karen L. Syrjala

Moderated by: Jessica R. Bauman

without cancer. Dr. Syrjala noted that some of these outcomes, such as symptoms of post-traumatic stress (different from a full diagnosis of PTSD) can persist for 10 to 15 years after diagnosis. Figure 1. Mental health outcomes in post

Full access

HSR21-070: Feasibility of Tracking Digital Activity, Sleep, and Patient-Reported Outcomes (PROs) in Newly Diagnosed Multiple Myeloma (NDMM) Patients (pts) Undergoing an In-Class Transition From Parenteral Bortezomib-Based Therapy to Oral Ixazomib-Lenalidomide-Dexamethasone (IRd) in the Ongoing Community-Based United States (US) MM-6 Study (NCT03173092)

Kirsten Stuber, Habte A. Yimer, Karin Choquette, Sudhir Manda, Jennifer Clayton, Saulius Girnius, Joshua Richter, Presley Whidden, Kimberly Bogard, Dasha Cherepanov, and Stephen J. Noga

(QoL) and improving outcomes. We evaluated the feasibility of digital actigraphy (monitoring activity/rest) and electronic PRO (ePRO) data collection using wearable and mobile devices in an older MM pt population (median age 73 years). Methods

Full access

Multidisciplinary Management of Pancreatic Cancer

Margaret A. Tempero

essentially be summarized as a half dozen clinical trials evaluating gemcitabine and 5-fluorouracil (FU), with and without radiation. Outcomes from these trials were largely similar, with median OS hovering around 22 months and 25% to 30% of patients dying of

Full access

Benefits of High-Volume Medical Oncology Care for Noncurable Pancreatic Adenocarcinoma: A Population-Based Analysis

Julie Hallet, Laura Davis, Alyson Mahar, Michail Mavros, Kaitlyn Beyfuss, Ying Liu, Calvin H.L. Law, Craig Earle, and Natalie Coburn

Background As medical and surgical therapies advance, cancer care has become increasingly complex. Clinical volume is an important construct in the delivery of specialized care, and provider volume has been associated with improved outcomes of